(RELX) Relx - Ratings and Ratios
Analytics, Data, Research, Legal, Exhibitions
Dividends
| Dividend Yield | 2.05% |
| Yield on Cost 5y | 3.89% |
| Yield CAGR 5y | 6.53% |
| Payout Consistency | 88.0% |
| Payout Ratio | 79.0% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 18.5% |
| Value at Risk 5%th | 31.2% |
| Relative Tail Risk | 2.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.68 |
| Alpha | -22.11 |
| CAGR/Max DD | 0.50 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.421 |
| Beta | 0.461 |
| Beta Downside | 0.335 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.49% |
| Mean DD | 4.28% |
| Median DD | 2.66% |
Description: RELX Relx September 25, 2025
RELX PLC (NYSE: REL) is a London-based information-services group that delivers analytics, data, and decision-support tools to professional customers worldwide. It operates through four distinct segments: Risk (public-and-industry data combined with algorithms to assess credit, fraud, and cyber risk); Scientific, Technical & Medical (research-grade data and platforms for scientists, clinicians, and pharma); Legal (regulatory, case-law, and business information that boosts legal-team productivity); and Exhibitions (hybrid physical-digital events that facilitate market discovery and sourcing). The company, formerly Reed Elsevier, rebranded to RELX in July 2015 and traces its corporate lineage to 1903.
According to the FY 2023 annual report (assumed to be the most recent filing), RELX generated £9.2 billion of revenue, with the Risk segment contributing roughly 38 % (£3.5 bn), Scientific, Technical & Medical 30 % (£2.8 bn), Legal 20 % (£1.8 bn), and Exhibitions the remaining 12 % (£1.1 bn). Operating profit was £2.4 bn, yielding an EBIT margin of ~26 %, and free cash flow exceeded £1.8 bn, supporting a dividend yield of about 3.6 % and a payout ratio near 70 %. Year-over-year revenue growth was modest (≈3 %) driven largely by pricing adjustments and modest organic expansion in the Risk and Legal businesses; Exhibitions rebounded from pandemic lows with a 9 % increase, reflecting renewed demand for in-person networking.
Key macro-drivers for RELX include: the accelerating regulatory environment that fuels demand for compliance and risk-analytics solutions; the surge in life-science R&D spending, which underpins growth in the Scientific, Technical & Medical segment; and the broader digital-transformation trend in legal services, where AI-enhanced research tools are gaining market share. Conversely, the Exhibitions segment remains sensitive to travel-related economic cycles and geopolitical uncertainty, which could introduce earnings volatility.
For analysts seeking a deeper, data-driven valuation of RELX’s growth levers and risk profile, a quick look at the company’s metrics on ValueRay can surface comparable peer multiples and scenario-analysis tools.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (3.82b TTM) > 0 and > 6% of Revenue (6% = 1.13b TTM) |
| FCFTA 0.35 (>2.0%) and ΔFCFTA 9.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -16.14% (prev -39.34%; Δ 23.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.37 (>3.0%) and CFO 5.31b > Net Income 3.82b (YES >=105%, WARN >=100%) |
| Net Debt (7.32b) to EBITDA (5.89b) ratio: 1.24 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.47 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.84b) change vs 12m ago -3.46% (target <= -2.0% for YES) |
| Gross Margin 64.67% (prev 61.09%; Δ 3.58pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 146.4% (prev 114.4%; Δ 32.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 6.21 (EBITDA TTM 5.89b / Interest Expense TTM 671.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.41
| (A) -0.21 = (Total Current Assets 2.73b - Total Current Liabilities 5.77b) / Total Assets 14.32b |
| (B) 0.13 = Retained Earnings (Balance) 1.89b / Total Assets 14.32b |
| (C) 0.32 = EBIT TTM 4.16b / Avg Total Assets 12.87b |
| (D) 0.18 = Book Value of Equity 2.22b / Total Liabilities 12.13b |
| Total Rating: 1.41 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.69
| 1. Piotroski 8.0pt |
| 2. FCF Yield 8.02% |
| 3. FCF Margin 26.69% |
| 4. Debt/Equity 3.46 |
| 5. Debt/Ebitda 1.24 |
| 6. ROIC - WACC (= 25.20)% |
| 7. RoE 123.8% |
| 8. Rev. Trend 94.83% |
| 9. EPS Trend 38.20% |
What is the price of RELX shares?
Over the past week, the price has changed by +1.49%, over one month by -13.85%, over three months by -16.06% and over the past year by -13.25%.
Is RELX a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the RELX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56.5 | 40.5% |
| Analysts Target Price | 56.5 | 40.5% |
| ValueRay Target Price | 41.8 | 4.1% |
RELX Fundamental Data Overview November 20, 2025
P/E Trailing = 29.6103
P/E Forward = 21.4133
P/S = 7.6834
P/B = 25.5367
P/EG = 2.0196
Beta = 0.283
Revenue TTM = 18.84b GBP
EBIT TTM = 4.16b GBP
EBITDA TTM = 5.89b GBP
Long Term Debt = 5.53b GBP (from longTermDebt, last quarter)
Short Term Debt = 1.94b GBP (from shortTermDebt, last quarter)
Debt = 7.54b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.32b GBP (from netDebt column, last quarter)
Enterprise Value = 62.68b GBP (55.36b + Debt 7.54b - CCE 211.0m)
Interest Coverage Ratio = 6.21 (Ebit TTM 4.16b / Interest Expense TTM 671.0m)
FCF Yield = 8.02% (FCF TTM 5.03b / Enterprise Value 62.68b)
FCF Margin = 26.69% (FCF TTM 5.03b / Revenue TTM 18.84b)
Net Margin = 20.26% (Net Income TTM 3.82b / Revenue TTM 18.84b)
Gross Margin = 64.67% ((Revenue TTM 18.84b - Cost of Revenue TTM 6.66b) / Revenue TTM)
Gross Margin QoQ = 66.25% (prev 64.72%)
Tobins Q-Ratio = 4.38 (Enterprise Value 62.68b / Total Assets 14.32b)
Interest Expense / Debt = 2.91% (Interest Expense 219.0m / Debt 7.54b)
Taxrate = 23.69% (304.0m / 1.28b)
NOPAT = 3.18b (EBIT 4.16b * (1 - 23.69%))
Current Ratio = 0.47 (Total Current Assets 2.73b / Total Current Liabilities 5.77b)
Debt / Equity = 3.46 (Debt 7.54b / totalStockholderEquity, last quarter 2.18b)
Debt / EBITDA = 1.24 (Net Debt 7.32b / EBITDA 5.89b)
Debt / FCF = 1.46 (Net Debt 7.32b / FCF TTM 5.03b)
Total Stockholder Equity = 3.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 26.65% (Net Income 3.82b / Total Assets 14.32b)
RoE = 123.8% (Net Income TTM 3.82b / Total Stockholder Equity 3.08b)
RoCE = 48.35% (EBIT 4.16b / Capital Employed (Equity 3.08b + L.T.Debt 5.53b))
RoIC = 32.25% (NOPAT 3.18b / Invested Capital 9.85b)
WACC = 7.05% (E(55.36b)/V(62.89b) * Re(7.71%) + D(7.54b)/V(62.89b) * Rd(2.91%) * (1-Tc(0.24)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -81.65 | Cagr: -1.39%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈4.20b ; Y1≈5.18b ; Y5≈8.84b
Fair Price DCF = 82.68 (DCF Value 150.39b / Shares Outstanding 1.82b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 38.20 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.83 | Revenue CAGR: 12.89% | SUE: N/A | # QB: 0
Additional Sources for RELX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle